Filter by: patients
Home > Community Treatment Reports and Side Effects > FTY720 (Fingolimod) Clinical Trial Treatment Report
What is FTY720 (Fingolimod) Clinical Trial?

FTY720 is the name used during clinical trials for the drug fingolimod. On September 22, 2010, fingolimod became the first oral disease modifying drug approved by the FDA as Gilenya to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 41 27 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Participate in clinical trial 14 9 Efficacy_major Efficacy_moderate Efficacy_cant_tell
Other 8 2 Efficacy_major Efficacy_none
Transplant rejection prevention 2 2 Efficacy_moderate Efficacy_cant_tell
placebo or drug 1 0
replacement for copaxone 1 0

See all 44 patients currently using FTY720 (Fingolimod) Clinical Trial

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 1
Moderate
 6
Mild
 10
None
 20

Commonly reported side effects, conditions, and hospitalizations associated with FTY720 (Fingolimod) Clinical Trial

Nausea 4
Slowed heart rate 3
Hair loss 3
Diarrhea 2
Shortness of breath (dyspnea) 2
Gas 2
See all 25 reported side effects ▼ See top 6 reported side effects ▲

Reported Schedules

  daily 0.25 mg daily 0.5 mg daily 1 other daily 1 daily 1 mg daily 1.25 mg daily 2.5 mg daily 5 mg daily 20 mg daily
  9 Number of Patients: 9 1 Number of Patients: 1 16 Number of Patients: 16 7 Number of Patients: 7 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Using FTY720 (Fingolimod) Clinical Trial (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 9   Other: 39%
Did not seem to work 6   Did not seem to work: 26%
Course of treatment ended 5   Course of treatment ended: 22%
Doctor's advice 5   Doctor's advice: 22%
Side effects too severe 3   Side effects too severe: 13%
Expense 1   Expense: 4%
Not indicated 1   Not indicated: 4%

See all 22 patients who’ve stopped using FTY720 (Fingolimod) Clinical Trial

Reported Duration See details about how long patients take this treatment ▼

Currently Using FTY720 (Fingolimod) Clinical Trial

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Using FTY720 (Fingolimod) Clinical Trial

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of FTY720 (Fingolimod) Clinical Trial

Always
 36 97%
Usually
 1 3%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of FTY720 (Fingolimod) Clinical Trial

Very
 2 5%
Somewhat
 0 0%
A little
 4 11%
Not at all
 31 84%

Cost

Paid out of pocket

Cost of FTY720 (Fingolimod) Clinical Trial

$200+
 1 4%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 26 96%

Report created on May 28, 2012.